Cargando…

Efficacy and safety of teneligliptin

Detalles Bibliográficos
Autor principal:	Singh, Awadhesh Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240050/ https://www.ncbi.nlm.nih.gov/pubmed/28217491 http://dx.doi.org/10.4103/2230-8210.193163

Ejemplares similares

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma, Surendra Kumar, et al.
Publicado: (2016)

Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy
por: Kumar, Amit, et al.
Publicado: (2019)

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Teneligliptin and “Thorough QTc study”: thorough enough?
por: Ghosal, Samit
Publicado: (2019)

Evaluation of the Safety and Efficacy of Teneligliptin at a Higher Dose in Indian Type 2 Diabetes Patients: A Retrospective Analysis
por: Mitra, Asis, et al.
Publicado: (2020)

Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study
por: Agarwal, Piyush, et al.
Publicado: (2018)

Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
por: Kadowaki, Takashi, et al.
Publicado: (2018)

Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Li, Xiaoxuan, et al.
Publicado: (2018)

Teneligliptin-induced hair loss: A case report
por: Agrawal, Prabhat K., et al.
Publicado: (2020)

Exanthematous Drug Eruption as a Side Effect of Teneligliptin
por: Sunil, Krupa A., et al.
Publicado: (2021)

Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
por: Haneda, Masakazu, et al.
Publicado: (2018)

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis
por: Okuda, Yoshinori, et al.
Publicado: (2016)

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice
por: Ceriello, Antonio, et al.
Publicado: (2019)

Therapeutic Effect of Teneligliptin in Drug-Induced Nephrotoxicity: An In-Vitro Study
por: Becerir, Tülay, et al.
Publicado: (2022)

QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)
por: Erande, S, et al.
Publicado: (2019)

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report
por: Kim, Hae Jin, et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2020)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Diffuse erythematous rash after teneligliptin therapy: A case report
por: Agrawal, Prabhat, et al.
Publicado: (2018)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
por: Ghosh, Sujoy, et al.
Publicado: (2016)

Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis
por: Singh, Awadhesh Kumar, et al.
Publicado: (2017)

Triglyceride and cardiovascular risk: A critical appraisal
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2019)

SAT-173 Antiproliferative Effect of Teneligliptin on Atherosclerosis in Vascular Smooth Muscle Cell
por: Moon, Shinje, et al.
Publicado: (2019)

Teneligliptin protects against ischemia/reperfusion-induced endothelial permeability in vivo and in vitro
por: Zhang, Lei, et al.
Publicado: (2020)

Editorial: Herd mentality, herds of migrants/people, and COVID-19 in India
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions
por: De Nigris, Valeria, et al.
Publicado: (2017)

Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes
por: Kutoh, Eiji, et al.
Publicado: (2014)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study
por: Kim, Hae Jin, et al.
Publicado: (2021)

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Ji, Linong, et al.
Publicado: (2020)

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
por: Ji, Linong, et al.
Publicado: (2021)

Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase‐4 inhibitors
por: Nakamaru, Yoshinobu, et al.
Publicado: (2016)

Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor
por: Takahara, Yusuke, et al.
Publicado: (2018)

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
por: Cho, Kyu Yong, et al.
Publicado: (2021)

Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin
por: Minezumi, Takumi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4a0c6mp4oear4rmjhbm2cket53